Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978013 | 0.72 | GAA (0.31) | MGLLGSK3AGSK3BGAA | |
| SCHEMBL175725 | 0.69 | MGLL (0.42) | MGLLGSK3AGSK3BGAAFAAH | |
| SCHEMBL515246 | 0.67 | — | — | |
| SCHEMBL7658483 | 0.67 | — | — | |
| SCHEMBL2922210 | 0.65 | — | — | |
| SCHEMBL2571475 | 0.65 | — | — | |
| SCHEMBL18282001 | 0.65 | — | — | |
| SCHEMBL28365068 | 0.61 | MGLL (0.35) | MGLLGSK3AGSK3BGAAFAAH | |
| SCHEMBL5551330 | 0.60 | ALDH1A1 (0.31) | GSK3AGSK3BALDH1A1BLM | |
| SCHEMBL22343462 | 0.60 | MGLL (0.31) | MGLLGSK3AGSK3BGAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114937771-A | Cathode material, preparation method thereof and lithium ion battery | 贝特瑞（江苏）新材料科技有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-10822313-B2 | Selective sulfonation of benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200157056-A1 | SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822313-B2 | Selective sulfonation of benzodiazepine derivatives | GABRA2, GABRA4, GABRA1 | MGLL 4858/4885GSK3A 1667/4885GSK3B 1484/4885 |
| US-20200157056-A1 | SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES | GABRA2, GABRA4, GABRA1 | MGLL 4858/4885GSK3A 1667/4885GSK3B 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.